{"id":66784,"date":"2020-11-19T16:44:21","date_gmt":"2020-11-19T15:44:21","guid":{"rendered":"https:\/\/cms.stage.munich-startup.gmbh\/?p=66784"},"modified":"2022-11-28T12:00:12","modified_gmt":"2022-11-28T11:00:12","slug":"catalym-erhaelt-50-millionen-euro-fuer-krebstherapie","status":"publish","type":"post","link":"https:\/\/cms.stage.munich-startup.gmbh\/en\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/","title":{"rendered":"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie"},"content":{"rendered":"<div class=\"entry-content\">\n<p>Catalym wurde 2016 gegr\u00fcndet und entwickelt eine spezielle Form der Krebstherapie. Dabei neutralisiert das <a href=\"https:\/\/www.catalym.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">von dem Startup entwickelte Molek\u00fcl CTL-002<\/a> ein spezielles Protein (GDF-15), welches Tumore nutzen, um sich vor dem k\u00f6rpereigenen Immunsystem zu sch\u00fctzen. Dadurch werden die Tumore f\u00fcr das Immunsystem wieder zug\u00e4nglich, was die Immunabwehr verst\u00e4rken soll. Zudem w\u00fcrden so neue Therapien m\u00f6glich und die Lebensqualit\u00e4t der Krebspatienten erh\u00f6ht.<\/p>\n\n\n\n<p>Die nun abgeschlossene Series-B wurde von Vesalius Biocapital III geleitet. Zudem beteiligten sich der Novartis Venture Fund (NVF), der Wachstumsfonds Bayern sowie die Partner- und Gr\u00fcndungsinvestoren Forbion und Biogeneration Ventures. Vertreter von Vesalius Biocapital III, NVF und Wachstumsfonds Bayern werden in diesem Zuge dem Verwaltungsrat beitreten.<\/p>\n\n\n\n<p><strong>Manfred R\u00fcdiger<\/strong>, CEO von Catalym, f\u00fchrt aus:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201eDieses Funding mit dem starken Engagement sowohl unserer bestehenden als auch neuer Investoren erm\u00f6glicht es uns, CTL-002 zum klinischen Wirksamkeitsnachweis zu bringen und festzustellen, dass die Neutralisierung von GDF-15 einer der wichtigsten Mechanismen zur Wiederherstellung des Immunsystems bei einer Vielzahl von Tumorarten ist. CTL-002 soll im Dezember 2020 in die klinische Entwicklung eintreten.&#8220;<\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">Catalym plant klinische Tests f\u00fcr Dezember<\/h2>\n\n\n\n<p><strong>Marc Lohrmann<\/strong>, gesch\u00e4ftsf\u00fchrender Gesellschafter von Vesalius BioCapital III, erkl\u00e4rte:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201eWir freuen uns sehr, uns Catalym in der Series-B-Runde anzuschlie\u00dfen und dazu beizutragen, dieses neue Paradigma der onkologischen Behandlung in einer ersten Humanstudie, die noch vor Ende 2020 beginnt, den Patienten n\u00e4her zu bringen.&#8220;<\/p><\/blockquote>\n\n\n\n<p><strong>Holger Reithinger<\/strong>, Aufsichtsratsvorsitzender von Catalym und General Partner bei Forbion, sagt:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201eDiese Finanzierung ist eine Anerkennung der Fortschritte, die das Team von Catalym in den letzten vier Jahren erzielt hat. Als Gr\u00fcndungsinvestor begr\u00fc\u00dfen wir unsere neuen Partner Vesalius Biocapital III, Novartis Venture Fund, Wachstumsfonds Bayern und Coparion, die gemeinsam mit uns die klinische Entwicklung von CTL-002 unterst\u00fctzen.&#8220;<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt. Die Finanzierungsrunde wurde von Vesalius Biocapital III angef\u00fchrt.<\/p>","protected":false},"author":33,"featured_media":66785,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5129,1],"tags":[371,4129,52],"class_list":["post-66784","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals","category-news","tag-biotech","tag-catalym","tag-finanzierung"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T15:44:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-28T11:00:12+00:00\" \/>\n<meta name=\"author\" content=\"Maximilian Feigl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maximilian Feigl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/\",\"name\":\"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"datePublished\":\"2020-11-19T15:44:21+00:00\",\"dateModified\":\"2022-11-28T11:00:12+00:00\",\"author\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/7450f959553c09d68e5880e15bc7a1b1\"},\"description\":\"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"contentUrl\":\"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Catalym\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/cms.stage.munich-startup.gmbh\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#website\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.stage.munich-startup.gmbh\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/7450f959553c09d68e5880e15bc7a1b1\",\"name\":\"Maximilian Feigl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2fb3c62c55df2ba1c4144195bb44ecd00690cf6349eb8bd534772464fb01e35c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2fb3c62c55df2ba1c4144195bb44ecd00690cf6349eb8bd534772464fb01e35c?s=96&d=mm&r=g\",\"caption\":\"Maximilian Feigl\"},\"description\":\"Maximilian Feigl berichtet seit 2020 \u00fcber das M\u00fcnchner Startup \u00d6kosystem. Dabei haben es dem studierten Politikwissenschaftler vor allem Deeptech-Themen angetan.\",\"url\":\"https:\/\/cms.stage.munich-startup.gmbh\/en\/author\/feigl\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup","description":"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.stage.munich-startup.gmbh\/en\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/","og_locale":"en_US","og_type":"article","og_title":"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup","og_description":"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.","og_url":"https:\/\/cms.stage.munich-startup.gmbh\/en\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/","og_site_name":"Munich Startup","article_published_time":"2020-11-19T15:44:21+00:00","article_modified_time":"2022-11-28T11:00:12+00:00","author":"Maximilian Feigl","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Maximilian Feigl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/","url":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/","name":"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie - Munich Startup","isPartOf":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage"},"image":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","datePublished":"2020-11-19T15:44:21+00:00","dateModified":"2022-11-28T11:00:12+00:00","author":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/7450f959553c09d68e5880e15bc7a1b1"},"description":"Das Biotech-Startup Catalym aus Planegg hat erfolgreich seine Series-B-Runde abgeschlossen und 50 Millionen Euro eingesammelt.","breadcrumb":{"@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#primaryimage","url":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","contentUrl":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","width":1920,"height":1280,"caption":"Catalym"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.stage.munich-startup.gmbh\/66784\/catalym-erhaelt-50-millionen-euro-fuer-krebstherapie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/cms.stage.munich-startup.gmbh\/"},{"@type":"ListItem","position":2,"name":"Catalym erh\u00e4lt 50 Millionen Euro f\u00fcr Krebstherapie"}]},{"@type":"WebSite","@id":"https:\/\/cms.stage.munich-startup.gmbh\/#website","url":"https:\/\/cms.stage.munich-startup.gmbh\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.stage.munich-startup.gmbh\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/7450f959553c09d68e5880e15bc7a1b1","name":"Maximilian Feigl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.stage.munich-startup.gmbh\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2fb3c62c55df2ba1c4144195bb44ecd00690cf6349eb8bd534772464fb01e35c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2fb3c62c55df2ba1c4144195bb44ecd00690cf6349eb8bd534772464fb01e35c?s=96&d=mm&r=g","caption":"Maximilian Feigl"},"description":"Maximilian Feigl has been reporting on the Munich startup ecosystem since 2020. The political science graduate is particularly interested in deep tech topics.","url":"https:\/\/cms.stage.munich-startup.gmbh\/en\/author\/feigl\/"}]},"og_image":[{"width":1920,"height":1280,"url":"https:\/\/cms.stage.munich-startup.gmbh\/wp-content\/uploads\/2020\/11\/medic-563423_1920.jpg","type":"image\/jpeg"}]},"_links":{"self":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/posts\/66784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/comments?post=66784"}],"version-history":[{"count":2,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/posts\/66784\/revisions"}],"predecessor-version":[{"id":66791,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/posts\/66784\/revisions\/66791"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/media\/66785"}],"wp:attachment":[{"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/media?parent=66784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/categories?post=66784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.stage.munich-startup.gmbh\/en\/wp-json\/wp\/v2\/tags?post=66784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}